IMUX Q2 2024 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$31,000

Operating Income

-$23M

Net Income

-$21M

EPS (Diluted)

$-0.21

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$86M

Total Liabilities

$23M

Stockholders' Equity

$64M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$31,000	$0	—
Operating Income	-$23M	-$25M	+8.8%
Net Income	-$21M	-$24M	+10.9%